These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23919476)

  • 1. Improved laboratory test methods for orally inhaled products.
    Mitchell JP; Nagel MW
    Ther Deliv; 2013 Aug; 4(8):1003-26. PubMed ID: 23919476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comparison of the Performance of Efficient Data Analysis Versus Fine Particle Dose as Metrics for the Quality Control of Aerodynamic Particle Size Distributions of Orally Inhaled Pharmaceuticals.
    Tougas TP; Goodey AP; Hardwell G; Mitchell J; Lyapustina S
    AAPS PharmSciTech; 2017 Feb; 18(2):451-461. PubMed ID: 27068528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Multi-laboratory in Vitro Study to Compare Data from Abbreviated and Pharmacopeial Impactor Measurements for Orally Inhaled Products: a Report of the European Aerosol Group (EPAG).
    Nichols SC; Mitchell JP; Sandell D; Andersson PU; Fischer M; Howald M; Pengilley R; Krüger P
    AAPS PharmSciTech; 2016 Dec; 17(6):1383-1392. PubMed ID: 26762338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of Passive Dry Powder Inhaler Aerodynamic Particle Size Distribution by Multi-Stage Cascade Impactor: International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) Recommendations to Support Both Product Quality Control and Clinical Programs.
    Mitchell JP; Stein SW; Doub W; Goodey AP; Christopher JD; Patel RB; Tougas TP; Lyapustina S
    AAPS PharmSciTech; 2019 May; 20(5):206. PubMed ID: 31147791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of Aerodynamic Particle Size Distribution of Orally Inhaled Products by Cascade Impactor: How to Let the Product Specification Drive the Quality Requirements of the Cascade Impactor.
    Roberts DL; Mitchell JP
    AAPS PharmSciTech; 2019 Jan; 20(2):57. PubMed ID: 30623259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Equivalence considerations for orally inhaled products for local action-ISAM/IPAC-RS European Workshop report.
    Evans C; Cipolla D; Chesworth T; Agurell E; Ahrens R; Conner D; Dissanayake S; Dolovich M; Doub W; Fuglsang A; García Arieta A; Golden M; Hermann R; Hochhaus G; Holmes S; Lafferty P; Lyapustina S; Nair P; O'Connor D; Parkins D; Peterson I; Reisner C; Sandell D; Singh GJ; Weda M; Watson P
    J Aerosol Med Pulm Drug Deliv; 2012 Jun; 25(3):117-39. PubMed ID: 22413806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addressing the Need for Controls on Particle Bounce and Re-entrainment in the Cascade Impactor and for the Mitigation of Electrostatic Charge for Aerodynamic Particle Size Assessment of Orally Inhaled Products: an Assessment by the International Consortium on Regulation and Science (IPAC-RS).
    Doub W; Stein S; Mitchell J; Goodey AP
    AAPS PharmSciTech; 2020 Aug; 21(7):239. PubMed ID: 32827121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 Aerodynamic Particle Sizer aerosol spectrometer.
    Mitchell JP; Nagel MW; Wiersema KJ; Doyle CC
    AAPS PharmSciTech; 2003 Oct; 4(4):E54. PubMed ID: 15198549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deposition of inhaled particles in the lungs.
    Fernández Tena A; Casan Clarà P
    Arch Bronconeumol; 2012 Jul; 48(7):240-6. PubMed ID: 22464044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orally inhaled drug performance testing for product development, registration, and quality control.
    Lastow O; Svensson M
    J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):401-7. PubMed ID: 25237712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs).
    Riley T; Christopher D; Arp J; Casazza A; Colombani A; Cooper A; Dey M; Maas J; Mitchell J; Reiners M; Sigari N; Tougas T; Lyapustina S
    AAPS PharmSciTech; 2012 Sep; 13(3):978-89. PubMed ID: 22798037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations.
    Hein S; Bur M; Schaefer UF; Lehr CM
    Eur J Pharm Biopharm; 2011 Jan; 77(1):132-8. PubMed ID: 20951200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishing bioequivalence for inhaled drugs; weighing the evidence.
    Daley-Yates PT; Parkins DA
    Expert Opin Drug Deliv; 2011 Oct; 8(10):1297-308. PubMed ID: 21699442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically Relevant In Vitro Testing of Orally Inhaled Products-Bridging the Gap Between the Lab and the Patient.
    Mitchell JP; Suggett J; Nagel M
    AAPS PharmSciTech; 2016 Aug; 17(4):787-804. PubMed ID: 27173990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of single versus multiple actuations on the particle size distribution of beclometasone dipropionate metered-dose inhalers.
    Feddah MR; Davies NM
    J Pharm Pharmacol; 2003 Aug; 55(8):1055-61. PubMed ID: 12956894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evaluation of dry powder inhaler devices of corticosteroid preparations.
    Tamura G; Sakae H; Fujino S
    Allergol Int; 2012 Mar; 61(1):149-54. PubMed ID: 22189592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report.
    Adams WP; Ahrens RC; Chen ML; Christopher D; Chowdhury BA; Conner DP; Dalby R; Fitzgerald K; Hendeles L; Hickey AJ; Hochhaus G; Laube BL; Lucas P; Lee SL; Lyapustina S; Li B; O'Connor D; Parikh N; Parkins DA; Peri P; Pitcairn GR; Riebe M; Roy P; Shah T; Singh GJ; Sharp SS; Suman JD; Weda M; Woodcock J; Yu L
    J Aerosol Med Pulm Drug Deliv; 2010 Feb; 23(1):1-29. PubMed ID: 20131983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methacholine dry powder inhaler as a new tool for bronchial challenge test.
    Colombo G; Terzano C; Colombo P; Petroianni A; Ricci A; Buttini F
    Int J Pharm; 2008 Mar; 352(1-2):165-71. PubMed ID: 18055141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do all dry powder inhalers show the same pharmaceutical performance?
    Taylor A; Gustafsson P
    Int J Clin Pract Suppl; 2005 Dec; (149):7-12. PubMed ID: 16279997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved quality control metrics for cascade impaction measurements of orally inhaled drug products (OIPs).
    Tougas TP; Christopher D; Mitchell JP; Strickland H; Wyka B; Van Oort M; Lyapustina S
    AAPS PharmSciTech; 2009; 10(4):1276-85. PubMed ID: 19882251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.